Author(s): <p style="text-align:justify">Venu Chippa , Swetha Chenna and Dilip Unnikrishnan</p>
Hydralazine was approved for hypertension by FDA in 1953 and it is one of the first antihypertensive medications that could be taken by mouth. In 2017 it is on the WHO’s list of essential medications, and 105th most prescribed medication in the United States. It is relatively very safe, common side effects include headache and increased heart rate. Prolonged use may cause a syndrome like lupus first reported in 1953 and occurs in 5 to 10% of patients taking hydralazine, presents with arthralgia, myalgia, fever, and serositis.
View PDF